Clinical spectrum and therapy of non-alcoholic steatohepatitis

Digestive Diseases

Volumn 30, Issue SUPPL. 1, 2012, Pages 69-73

  Day, Christopher Paul ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Fatty liver; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Steatosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETAINE; CLOFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; METFORMIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PROBUCOL; ROSIGLITAZONE;

AEROBIC EXERCISE; ALCOHOL CONSUMPTION; APOPTOSIS; ARTICLE; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BILIOPANCREATIC BYPASS; DIABETIC PATIENT; DIET THERAPY; DISEASE CLASSIFICATION; DRUG FATALITY; ECHOGRAPHY; FATTY LIVER; FRACTURE; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SIDE EFFECT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; STELLATE CELL;

BIOLOGICAL MARKERS; FATTY LIVER; HUMANS; LIVER; METABOLIC SYNDROME X;

EID: 84867733505     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341128     Document Type: Article

References (36)

1. Machado M, Marques-Vidal P, Cortez-Pinto H: Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600-606. (Pubitemid 44307393)
2. Targher G, Bertolini L, Padovani R, et al: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218. (Pubitemid 46684650)
3. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH: Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.
4. Sanyal AJ, Banas C, Sargeant C, et al: Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689.
5. Ekstedt M, Franzen LE, Mathiesen UL, et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873. (Pubitemid 46489550)
6. Younossi ZM, Stepanova M, Rafiq N, et al: Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874-1882.
7. Targher G, Day CP, Bonora E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
8. Newton JL, Jones DEJ, Henderson E, et al: Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57: 807-813. (Pubitemid 351716975)
9. Browning JS, Dobbins LS, Nuremberg R, et al: Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-1395.
10. Cerda C, Perez-Ayuso RM, Riquelme A, et al: Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47: 412-417. (Pubitemid 47176161)
11. Javor E, Ghany M, Cochran E, et al: Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41: 753-760. (Pubitemid 40462937)
12. Yoneda M, Yoneda M, Mawatari H, et al: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Gut 2008; 56: 1330-1331.
13. Nobili V, Vizzutti F, Arena U, et al: Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442-448.
14. Saadeh S, Younossi ZM, Remer ME, et al: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750. (Pubitemid 34977081)
15. Ratziu V, Bellentani S, Cortez-Pinto H, Day CP, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 Special Conference. J Hepatol 2010; 53: 372-384.
16. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP: Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269.
17. Day CP: From fat to inflammation. Gastroenterology 2006; 130: 207-210. (Pubitemid 43049850)
18. Promrat K, Kleiner DE, Niemeier HM, et al: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129.
19. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor RW, Day CP, Trenell MI: Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-1283.
20. Lavine JE, Schwimmer JB, van Natta M, et al: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. The TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668.
21. Sanyal AJ, Chalasani N, Kowdley KV, et al: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
22. Loke YK, Kwok CS, Singh S: Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studies. Br Med J 2011; 342:d1309.
23. Browning J: Statins and hepatic steatosis: Perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-471. (Pubitemid 44214886)
24. Parker HM, Johnson NA, Burdon CA, et al: Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2012; 56: 944-951.
25. Yokohama S, Yoneda M, Haneda M, et al: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225. (Pubitemid 39425579)
26. De Alwis NM, Day CP: Current and future therapeutic strategies in NAFLD. Curr Pharm Des 2010; 16: 1958-1962.
27. Dufour JF, Oneta CM, Gonvers JJ, et al: Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543. (Pubitemid 44880031)
28. Klein EA, Thompson IM, Tangen CM, et al: Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011; 306: 1549-1556.
29. Zein CO, Yerian LM, Gogate P, et al: Pentoxifylline improves nonalcoholic steatohepatitis: A randomized, placebo-controlled trial. Hepatology 2011; 54: 1610-1619.
30. Ratziu V, Sheikh MY, Sanyal AJ, et al: A phase 2, randomized, double-blind placebocontrolled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55: 419-428.
31. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith R, Gorgun C, et al: Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-1140. (Pubitemid 44300242)
32. Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, de Vos R, Roskams T, Trautwein C: Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 2008; 57: 655-663. (Pubitemid 351579980)
33. Zhang S, Wang J, Liu Q, Harnish DC: Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009; 51: 380-388.
34. Lee JM, Lee YK, Mamrosh JL, et al: A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature 2011; 474: 506-512.
35. Contos MJ, Cales W, Sterling RK, et al: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-373. (Pubitemid 32331542)
36. Ong J, Younossi ZM, Reddy V, et al: Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801. (Pubitemid 32851301)